Core B: Molecular Biol. Genetics Core

分子生物学和遗传学核心实验室自芝加哥大学以来一直在运营 糖尿病中心于1977年首次获得资助，对核心名称进行了微小的更改，但有了一个主要的 重点是分子生物学和最近的遗传学。这一核心帮助独立资助 对在糖尿病和糖尿病研究中使用分子和遗传学方法感兴趣的研究人员 其他代谢性疾病以及糖尿病并发症。对基因服务日益增长的需求已经 导致该核心主要专注于提供针对糖尿病基因研究的服务 包括研究设计、能量计算、样本收集、基因分型和测序以及数据 分析。核心不仅服务于DRTC研究人员，也服务于糖尿病研究人员进行基因 在美国和国际上对糖尿病的研究。核心不仅提供服务，还提供 提供建议和实践培训。在这场竞争性的更新中，重点将继续放在基因上 研究包括全基因组关联研究和整合全外显子组和全基因组的设计 测序方法。我们还建议开发与糖尿病相关的数据库，以便 所有与单基因形式的糖尿病和多基因形式的变异相关的突变列表 糖尿病的症状。虽然这个核心的重点主要是遗传学，但我们认识到这样一个事实，即遗传学 研究导致生物学研究。因此，我们建议将BAC重组工程作为一项新服务提供给 研究人员在体内和体外研究糖尿病基因的生物学。贝尔博士和考克斯博士将继续 担任本核心的董事和联席董事。马塞洛·诺布雷加博士将作为联席主任领导他们 BAC重组工程服务。该小组将由流行病学(Hanis)领域的领导人提供建议 和Ober)、遗传分析(Abney、Di Rienzo、Nicolae、Pritchard和Stephens)、生物统计学(Nicolae和 斯蒂芬斯)、计算(网格和云计算--福斯特和格罗斯曼)以及基因组学和系统 生物学(怀特)确保核心服务处于复合体遗传和基因组研究的前沿 疾病，并快速适应用户需求。

The Molecular Biology and Genetics Core Laboratory has been in operation since the University of Chicago Diabetes Center was first funded in 1977 with minor changes in the name of the core but with a major emphasis on molecular biology and more recently genetics. This Core helps independently funded investigators who are interested in using molecular and genetic approaches in the study of diabetes and other metabolic diseases as well as diabetic complications. The growing demand for genetic services has resulted in this Core largely focusing on providing services directed towards genetic studies of diabetes including study design, power calculations, sample collection, genotyping and sequencing, and data analysis. The Core serves not only DRTC investigators but also diabetes investigators carrying out genetic studies of diabetes throughout the United States and internationally. The Core offers services as well as providing advice and hands-on training. In this competing renewal the focus will continue to be on genetic studies including genome-wide association study and design incorporating whole-exome and whole-genome sequencing approaches. We also propose to develop "diabetes-related databases" that will be accessible to all such as lists of mutations associated with monogenic forms of diabetes and variants with polygenic forms of diabetes. While the focus of this Core is primarily genetics, we are cognizant of the fact that genetic studies lead to biological studies. Thus, we propose to offer BAC recombineering as a new service for investigators studying the biology of diabetes genes in vivo and in vitro. Drs. Bell and Cox will continue to serve as Director and Co-Director of this Core. Dr. Marcelo Nobrega will join them as a Co-Director leading the BAC recombineering service. This group will be advised by leaders in the field of epidemiology (Hanis and Ober), genetic analysis (Abney, Di Rienzo, Nicolae, Pritchard and Stephens), biostatistics (Nicolae and Stephens), computation (grid and cloud computing - Foster and Grossman) and genomics and systems biology (White) to ensure that Core services are at the forefront of genetic and genomic studies of complex diseases and quickly adapts to users needs.